Life Sciences Law & Industry Report connects the dots among the many disciplines that make up the burgeoning life sciences industry, with biweekly updates on current regulatory, legislative,...
Nov. 4 — Biotech revenue and research and development expenditures grew in 2014, but concern about drug prices has made industry investors skittish, according to a briefing summary released Nov. 4.
The 2015 BDO Biotech briefing said that biotech companies' average research and development expenditures reached $55.6 million in 2014, up from $47.1 million in 2013 and $40.7 million in 2012.
Global revenue among all biotechs jumped 44 percent to $67.1 million in 2014, up from $46.6 million the year before, and novel new drug approvals hit an 18-year high with a total of 41 new molecular entities (NMEs) receiving Food and Drug Administration approval (9 LSLR 107, 1/23/15).
The briefing said that the high pace of drug approvals has continued this year, with 29 NMEs approved as of October.
Ryan Starkes, life sciences practice leader at the tax, financial advisory and consulting firm BDO USA LLP, said, “Optimism surrounding the opportunities for further drug development in light of a continued increase in the approval of new drugs by the FDA supports investment in R&D. However, political controversy and widespread criticism around rising drug prices has made investors skittish, and we have seen that recently reflected in valuations.”
The BDO Biotech Briefing examined the most recent 10-K filings with the Securities and Exchange Commission of companies listed on the Nasdaq Biotechnology Index. Companies reporting more than $300 million in revenue were excluded to ensure findings are representative of the vast majority of companies included in the index.
The briefing found that large biotechs—from $50 million to $300 million in revenue—experienced the greatest increase in global revenue in 2014, growing average revenue by 52 percent to $129.3 million. Small biotechs reported a 7 percent increase in average revenue, up from a decrease of 21 percent in 2013.
• Debt Financing Doubles. While the bulk of biotechs secured financing through the equity markets, those that sought debt financing raised much larger amounts. Seventy-one percent of biotechs secured equity financing, whereas only 34 percent of companies secured financing through the credit markets. Companies seeking debt financing raised an average of $128.6 million, nearly double the average size of 2013 financings, with large biotechs demonstrating an ability to secure more than twice the average amount of debt financing of smaller biotechs.
• Biotech Hiring Spree. Biotechs continued to demonstrate a high level of hiring activity, reporting an average of 216 employees overall in 2014, 20.7 percent higher than 2013 levels.
• More Cash Reserves, More Time to Invest. With a focus on growth and R&D-led innovation, biotech companies are growing their cash reserves, the briefing said. In 2014, biotechs reported an average of $180.3 million in liquid assets, up 43 percent from 2013 and almost 100 percent from 2012 levels.
• Shareholder Returns Boost IPO Valuations. In 2014, biotechs drew an average total shareholder return—which combines share price appreciation and dividends paid to show the total return to the shareholder expressed as an annualized percentage—of 113 percent, up from 97 percent the previous year. In addition, the average market cap of companies studied, as of the end of their most recent fiscal year, surpassed the billion-dollar mark, reaching $1.14 billion, compared to $881 million in 2013. Fueled by strong returns and investor appetite, biotech initial public offering (IPO) activity was strong in 2014 and the first part of 2015.
The briefing also indicated that 2014 was a strong year for mergers and acquisitions, with the biopharma industry reaching a record $202 billion in them.
And 2015 has sustained this level, the briefing said, with nearly a fourth (23.6 percent) of companies on the Nasdaq Biotechnology Index engaging in M&A this year. According to Dealogic data, the first three quarters, through Sept. 4, brought 302 biopharma deals, totaling $235 billion.
The third quarter was a rough one for the biotech industry, BDO said. But Aftab Jamil, BDO partner and leader of the technology and life sciences practice, said, “Despite the current slump in biotech stock prices and IPOs, appetite for M&A remains strong, and we can expect deal activity to continue at a moderate pace. The electoral focus on health care reform and public frustration around rising drug prices will create some investor hesitation, but increased excitement about drug development presents an opportunity for future industry growth.”
To contact the reporter on this story: John T. Aquino in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Lee Barnes at email@example.com
A summary of the report is at https://www.bdo.com/news/2015-november/biotech-fever-drives-boom-in-r-d-spending-revenue.
A BDO spokeswoman told Bloomberg BNA in a Nov. 4 e-mail that the full report is still in development and will be available at https://www.bdo.com/.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)